{"id":"atorvastatin-alone","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1-2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition leads to decreased hepatic cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:00.901Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT02432534","phase":"PHASE2","title":"Atorvastatin in Active Vitiligo","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-05","conditions":"Vitiligo","enrollment":28},{"nctId":"NCT06686615","phase":"","title":"A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2025-02-12","conditions":"Primary Hypercholesterolemiia, Mixed Dyslipidemia","enrollment":2000},{"nctId":"NCT06696820","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2024-11-29","conditions":"Acute Ischemic Stroke","enrollment":429},{"nctId":"NCT07268625","phase":"PHASE1","title":"Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-12-09","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT07235189","phase":"PHASE1","title":"A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2025-10-28","conditions":"Healthy Subjects","enrollment":58},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT06615284","phase":"PHASE1","title":"A Study of Atorvo+™ in Healthy Adult Participants","status":"COMPLETED","sponsor":"Indication Bioscience LLC","startDate":"2025-01-28","conditions":"Coronary Heart Disease, Dyslipidemias","enrollment":24},{"nctId":"NCT07012629","phase":"PHASE3","title":"A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI)","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-26","conditions":"Covert Brain Infarction","enrollment":1652},{"nctId":"NCT05559164","phase":"PHASE2","title":"Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-09-19","conditions":"Cardiac Toxicity, Early-stage Breast Cancer","enrollment":60},{"nctId":"NCT06948747","phase":"PHASE1","title":"A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-05-06","conditions":"Healthy Participants","enrollment":49},{"nctId":"NCT07197463","phase":"NA","title":"The Therapeutic Effect of Phase I Cardiac Rehabilitation on Elderly Patients With CHD Complicated by Sarcopenia","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2025-10-10","conditions":"Coronary Disease, Sarcopenia","enrollment":100},{"nctId":"NCT06358313","phase":"PHASE3","title":"Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT06360120","phase":"PHASE3","title":"Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-04-10","conditions":"Ischemic Stroke","enrollment":600},{"nctId":"NCT02603328","phase":"PHASE1, PHASE2","title":"Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-07-17","conditions":"Cerebral Cavernous Malformation","enrollment":80},{"nctId":"NCT07128212","phase":"NA","title":"Atorvastatin Mitigates WMH-Related Cognitive Impairment by Reducing VCAM-1","status":"COMPLETED","sponsor":"Suzhou Municipal Hospital of Anhui Province","startDate":"2021-01-01","conditions":"Ischemic White Matter Lesions (WMIL), Cerebral Small Vessel Disease, Vascular Cell Adhesion Molecule-1","enrollment":401},{"nctId":"NCT07121088","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08-31","conditions":"Ischemic Cerebral Infarction, Diabetes Mellitus","enrollment":3666},{"nctId":"NCT06567327","phase":"PHASE1","title":"A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-08-28","conditions":"Obesity","enrollment":82},{"nctId":"NCT07088523","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-07-31","conditions":"Diabete Mellitus, Ischemic Cardiovascular Disease","enrollment":4205},{"nctId":"NCT04972396","phase":"PHASE1","title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-09-15","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":40},{"nctId":"NCT06723691","phase":"PHASE1","title":"Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects","status":"COMPLETED","sponsor":"Fujian Shengdi Pharmaceutical Co., Ltd.","startDate":"2024-12-18","conditions":"Type 2 Diabetes","enrollment":57},{"nctId":"NCT06289504","phase":"PHASE1","title":"A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-27","conditions":"Obesity","enrollment":34},{"nctId":"NCT04536870","phase":"NA","title":"Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2019-12-12","conditions":"Heart Failure, Atrial Fibrillation, Healthy Ageing","enrollment":369},{"nctId":"NCT04388501","phase":"PHASE1","title":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2021-06-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT02098460","phase":"PHASE4","title":"To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2013-10","conditions":"Severe Hypercholesterolemia","enrollment":300},{"nctId":"NCT04824911","phase":"PHASE2","title":"Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-03-23","conditions":"Acute Stroke, Dual Antiplatelet Therapy, Statin","enrollment":376},{"nctId":"NCT05342974","phase":"EARLY_PHASE1","title":"Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2022-04-19","conditions":"Abortion Early","enrollment":9},{"nctId":"NCT03753555","phase":"PHASE4","title":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-01","conditions":"Stroke, Ischemic, Atherosclerosis, Cerebral","enrollment":100},{"nctId":"NCT06871358","phase":"NA","title":"The Effect of Atorvastatin 80 mg on Hs-CRP/Albumin Ratio in Reducing Thrombus Burden in PCI-STEMI Patients","status":"COMPLETED","sponsor":"Universitas Sebelas Maret","startDate":"2024-09-01","conditions":"STEMI (STE-ACS), Primary PCI for STEMI","enrollment":40},{"nctId":"NCT06191991","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2023-11-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT06699355","phase":"PHASE1","title":"A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-11-08","conditions":"Healthy","enrollment":18},{"nctId":"NCT06684366","phase":"","title":"Chronic Coronary Syndrome Real Practice and Guidelines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assiut University","startDate":"2024-10-22","conditions":"Coronary Arterial Disease (CAD)","enrollment":300},{"nctId":"NCT06601517","phase":"PHASE1","title":"A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.","status":"NOT_YET_RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2024-10","conditions":"Healthy Adult Subject, Overweight Subject","enrollment":30},{"nctId":"NCT05093205","phase":"PHASE1","title":"STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-25","conditions":"Healthy Adults","enrollment":35},{"nctId":"NCT02726555","phase":"PHASE3","title":"The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin","status":"RECRUITING","sponsor":"Wenzhou Medical University","startDate":"2015-11","conditions":"Dyslipidemia, Atherosclerosis","enrollment":240},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT04270370","phase":"PHASE1","title":"A Study of LY3478045 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-03-16","conditions":"Healthy","enrollment":72},{"nctId":"NCT06293742","phase":"PHASE1","title":"ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants","status":"COMPLETED","sponsor":"Eccogene","startDate":"2024-02-08","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT06364124","phase":"NA","title":"Effects of PCSK-9 Inhibitor Treatment Prior to Undergoing Primary Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction","status":"RECRUITING","sponsor":"Beijing Luhe Hospital","startDate":"2023-06-01","conditions":"STEMI","enrollment":84},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT03882892","phase":"PHASE3","title":"Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-02-02","conditions":"Hypercholesterolemia","enrollment":400},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT05764317","phase":"","title":"Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2023-04-30","conditions":"Arterial Hypertension, HTN","enrollment":409},{"nctId":"NCT05361421","phase":"PHASE4","title":"Effect of Intensive LDL-cholesterol Targeting for Elderly Patients With Cardiovascular Disease: I-OLD Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-07-19","conditions":"Cardiovascular Disease","enrollment":1200},{"nctId":"NCT01563731","phase":"PHASE4","title":"Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2013-04","conditions":"Stroke, Transient Ischemic Attack, Hypertension","enrollment":200},{"nctId":"NCT06262685","phase":"PHASE4","title":"Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2024-03-04","conditions":"Cardiovascular Diseases, Dyslipidemias, Statin Adverse Reaction","enrollment":216},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT05642845","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting Conditions","status":"COMPLETED","sponsor":"Pharmtechnology LLC","startDate":"2022-11-19","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT04721795","phase":"PHASE2, PHASE3","title":"Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)","status":"COMPLETED","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2021-01-19","conditions":"Tuberculosis, Pulmonary, Tuberculosis","enrollment":150},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT06134635","phase":"","title":"Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-12-01","conditions":"Acute Ischemic Stroke","enrollment":80},{"nctId":"NCT05815680","phase":"PHASE1","title":"A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-04-06","conditions":"Overweight Subjects, Obese Subjects","enrollment":48},{"nctId":"NCT05996978","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke Caused by Severe Intracranial Arterial Stenosis","status":"COMPLETED","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2020-02-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT03703635","phase":"NA","title":"Balloon Angioplasty for Symptomatic Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Ministry of Science and Technology of the People´s Republic of China","startDate":"2018-10-17","conditions":"Intracranial Artery Stenosis","enrollment":512},{"nctId":"NCT05681273","phase":"PHASE1","title":"Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.","status":"COMPLETED","sponsor":"Chipscreen Biosciences, Ltd.","startDate":"2023-02-17","conditions":"T2DM","enrollment":48},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT05870007","phase":"PHASE2","title":"Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2023-05","conditions":"Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT01665677","phase":"PHASE2","title":"Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation","status":"COMPLETED","sponsor":"Mehdi Hamadani","startDate":"2014-01-20","conditions":"Graft vs Host Disease","enrollment":69},{"nctId":"NCT05697185","phase":"PHASE4","title":"Safety and Efficacy of Evolocumab in Ischemic Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangxi Medical University","startDate":"2023-02-01","conditions":"Ischemic Stroke, Acute","enrollment":200},{"nctId":"NCT05679102","phase":"NA","title":"Atorvastatin as an Antihypertensive Agent","status":"COMPLETED","sponsor":"Himayat Ullah","startDate":"2022-12-20","conditions":"Atorvastatin Antihypertensive Effect","enrollment":120},{"nctId":"NCT05620615","phase":"","title":"Intensive Drug Therapy for Ischemic Stroke","status":"UNKNOWN","sponsor":"Shanghai Yueyang Integrated Medicine Hospital","startDate":"2018-07-01","conditions":"Ischemic Stroke","enrollment":42},{"nctId":"NCT05103644","phase":"PHASE2, PHASE3","title":"Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2021-10-30","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT05583643","phase":"PHASE1","title":"Clinical & Biochemical Effect of Atorvastatin in Nano Particles Gel in Periodontitis Treatment","status":"COMPLETED","sponsor":"Misr University for Science and Technology","startDate":"2021-12-07","conditions":"Periodontitis","enrollment":24},{"nctId":"NCT05555238","phase":"","title":"An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2020-01-16","conditions":"Dyslipidemia","enrollment":1716},{"nctId":"NCT01516879","phase":"PHASE3","title":"Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-01-05","conditions":"Hypercholesterolemia","enrollment":905},{"nctId":"NCT04974814","phase":"NA","title":"Effect of Statin Preloading in STEMI in Improving PCI Outcomes","status":"UNKNOWN","sponsor":"Beni-Suef University","startDate":"2021-05-26","conditions":"ST Elevation Myocardial Infarction","enrollment":99},{"nctId":"NCT04608344","phase":"PHASE1","title":"Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-11-04","conditions":"Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT00715273","phase":"PHASE4","title":"Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication","status":"COMPLETED","sponsor":"University of Washington","startDate":"2001-05-01","conditions":"Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis","enrollment":217},{"nctId":"NCT02245087","phase":"PHASE2","title":"Eliminate Coronary Artery Disease","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2014-08","conditions":"Coronary Artery Disease","enrollment":28},{"nctId":"NCT04581759","phase":"NA","title":"Endovascular Treatment and RIPC in Acute Ischemic Stroke","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-04-12","conditions":"Acute Ischemic Stroke, Endovascular Treatment","enrollment":300},{"nctId":"NCT05298475","phase":"PHASE4","title":"Low-dose PCSK9 Inhibitor Combined With Stains on Serum Lipids in Chinese Population With Acute Coronary Syndrome","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-04-01","conditions":"Acute Coronary Syndrome","enrollment":100},{"nctId":"NCT02476006","phase":"PHASE3","title":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-06-23","conditions":"Hypercholesterolemia","enrollment":998},{"nctId":"NCT00651404","phase":"PHASE3","title":"Ezetimibe Plus Atorvastatin Versus Atorvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03406)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-01","conditions":"Hypercholesterolemia, Atherosclerosis","enrollment":137},{"nctId":"NCT00319449","phase":"PHASE4","title":"Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-09","conditions":"Hypercholesterolemia, Coronary Arteriosclerosis","enrollment":22},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT03692754","phase":"PHASE2, PHASE3","title":"Atorvastatin in Management of Newly Diagnosed ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-01","conditions":"Immune Thrombocytopenia, Purpura, Thrombocytopenic","enrollment":30},{"nctId":"NCT03318484","phase":"PHASE1, PHASE2","title":"Sonodynamic Therapy on Patients With Femoropopliteal PAD and Claudication","status":"WITHDRAWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2017-11","conditions":"Peripheral Arterial Disease, Atherosclerosis, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT03218293","phase":"NA","title":"Thrombolysis and RIPC in Acute Ischemic Stroke","status":"COMPLETED","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2017-08-01","conditions":"Acute Ischemic Stroke, Cerebral Embolism and Thrombosis","enrollment":68},{"nctId":"NCT04486508","phase":"PHASE3","title":"Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Covid19","enrollment":600},{"nctId":"NCT03110848","phase":"PHASE2","title":"Effects of Atorvastatin in Graves' Orbitopathy (GO)","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2020-06-01","conditions":"Thyroid Associated Ophthalmopathy, Hypercholesterolemia","enrollment":88},{"nctId":"NCT03355027","phase":"NA","title":"Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-11-30","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":60},{"nctId":"NCT02714569","phase":"PHASE1","title":"A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Dyslipidemias","enrollment":60},{"nctId":"NCT00540293","phase":"PHASE4","title":"Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-10","conditions":"Dyslipidemias","enrollment":425},{"nctId":"NCT00917579","phase":"PHASE4","title":"Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Hypercholesterolemia","enrollment":76},{"nctId":"NCT00844376","phase":"PHASE4","title":"Bioavailability Study for New Atorvastatin Formulation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-02","conditions":"Hypercholesterolemia","enrollment":12},{"nctId":"NCT00917644","phase":"PHASE4","title":"Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-07","conditions":"Hypercholesterolemia","enrollment":76},{"nctId":"NCT02565615","phase":"","title":"Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2016-06-22","conditions":"Coronary Artery Disease, Hypercholesterolemia, Hypertension","enrollment":5115},{"nctId":"NCT00442325","phase":"PHASE4","title":"Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident","enrollment":595},{"nctId":"NCT00645151","phase":"PHASE4","title":"A Study Of The Efficacy Of Atorvastatin In Lowering Cholesterol In Latin American Patients With High Cholesterol","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-04","conditions":"Dyslipidemias","enrollment":512},{"nctId":"NCT00644670","phase":"PHASE4","title":"A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-06","conditions":"Dyslipidemias","enrollment":232},{"nctId":"NCT00151502","phase":"PHASE3","title":"To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-11","conditions":"Alzheimer's Disease","enrollment":600},{"nctId":"NCT00777517","phase":"PHASE1","title":"Bioequivalence Study On Pediatric Appropriate Formulation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-11","conditions":"Hypercholesterolemia","enrollment":76},{"nctId":"NCT00442845","phase":"PHASE4","title":"Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-01","conditions":"Coronary Arteriosclerosis, Diabetes Mellitus, Type 2, Cerebrovascular Accident","enrollment":2080},{"nctId":"NCT00758004","phase":"PHASE1","title":"Bioequivalence Study Of Pediatric Appropriate Formulation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-10","conditions":"Hypercholesterolemia","enrollment":76},{"nctId":"NCT00647543","phase":"PHASE4","title":"Atorvastatin Study For The Treatment Of High Cholesterol In Patients From Thailand","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-08","conditions":"Dyslipidemias","enrollment":242},{"nctId":"NCT00150371","phase":"PHASE3","title":"Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-06","conditions":"Hypercholesterolemia","enrollment":1100},{"nctId":"NCT04754789","phase":"PHASE3","title":"Effect of Upstream Treatment With High Intensity Statin on the Outcomes of STMI Patients Treated With PPCI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-02-20","conditions":"ST Elevation Myocardial Infarction","enrollment":160},{"nctId":"NCT00412113","phase":"PHASE4","title":"A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2007-01","conditions":"Dyslipidemia, Hypertension","enrollment":245},{"nctId":"NCT01107743","phase":"","title":"Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-06","conditions":"Hypertension, Angina Pectoris, Hypercholesterolemia","enrollment":1291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":190,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lipitor"],"phase":"phase_3","status":"active","brandName":"Atorvastatin alone","genericName":"Atorvastatin alone","companyName":"Wenzhou Medical University","companyId":"wenzhou-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}